Delivery Order SPE2DB22D1106-SPE2DB25FFCY2
- Not listed
- The Defense Logistics Agency awarded a $9,374.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion scheduled for September 29, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with performance completion by September 30, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal contracting vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of July 11, 2025. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be completed by September 3, 2025, with fulfillment conducted from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,061.54 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded procurement. Performance will be completed by September 5, 2025, with the product supplied from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency awarded a $28,123.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, with an ultimate completion date of September 10, 2025, represents a non-set-aside competitive award executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCY2Delivery Order
The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency and U.S. Coast Guard healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to supply a broad spectrum of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Tezspire is a biologic medication used in the treatment of severe asthma, reflecting AmerisourceBergen's role in providing specialized pharmaceutical commodities to support military and veteran healthcare needs through DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.2k | 8/12/25 |